{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "DXCM",
  "name": "DexCom, Inc.",
  "url": "https://orbyd.app/dossiers/DXCM/",
  "json_url": "https://orbyd.app/dossiers/DXCM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-the published invalidation levels still under the 200-EMA and the confirmed July 30 Q2 print is the binary; buying here chases extension into earnings risk.",
  "invalidation_trigger": "a daily close that breaches the risk threshold loses the recovery-base shelf and round number; secondarily, a Q2 miss or guide-down on the July 30 print, an Abbott Libre price/share headline, or the medtech-diagnostics theme flipping to SATURATED would confirm the break.",
  "catalyst_date": "2026-07-30",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-22",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings expected ~late July (no firm date yet) — next hard binary; avoid fresh chase into the print once confirmed.",
    "Bull thesis hinges on Type 2 non-insulin REIMBURSEMENT, not just A1C data — payer coverage lags clinical wins by quarters; watch for coverage announcements.",
    "Structure is a recovery bounce: 50-EMA below 200-EMA, advance unconfirmed by volume (~0.74x). A 200-EMA reclaim on >1.3x volume converts bounce to trend.",
    "GLP-1 displacement bear thesis (Lilly/Novo) is the structural overhang; CONNECT Type 2 non-insulin data is the counter-argument.",
    "Catalyst window is post-event: ADA (6/5-8), CONNECT (6/8), OTC pediatric clearance (6/12) all already printed — narrative now rides analyst revisions and rollout execution.",
    "Q2 2026 earnings ~late July (est. 7/23, no firm date confirmed) — next hard binary; avoid a fresh chase into the print once dated.",
    "Structure is a recovery bounce: 50-EMA below 200-EMA, advance unconfirmed (~0.74x volume). A 200-EMA reclaim on >1.3x volume converts bounce to trend.",
    "Catalyst window is post-event: ADA (6/5-8), CONNECT (6/8), OTC pediatric / Stelo expansion (6/15) all printed — narrative now rides analyst revisions and rollout execution.",
    "Analyst cluster late June: Stifel $90, TD Cowen $95, Piper $88, Deutsche Bank $86 (Buy initiation 6/23), Mizuho $85 — PTs sit only modestly above the high-the published invalidation levels tape, so reward/risk on a chase is compressed.",
    "Q2 2026 earnings CONFIRMED 2026-07-30 after the close (4:30 p.m. ET) — the prior 7/23 estimate was wrong; this is the next hard binary, avoid a fresh chase into the print.",
    "Structure is a recovery bounce: still contending with the 200-EMA from below; June advance ran ~0.74x volume. A 200-EMA reclaim on >1.3x volume converts bounce to trend.",
    "GLP-1 displacement (Lilly/Novo) is the structural overhang; CONNECT Type 2 non-insulin data (G7 −1.6% A1C over 26 weeks) is the counter-argument.",
    "Analyst cluster mid-July: Mizuho $90 (7/15), Truist $87 (7/16) atop DB $86, Piper $88, TD Cowen $95, Stifel $90; consensus ~$85 across 27 analysts — PTs only modestly above the high-the published invalidation levels tape, so reward/risk on a chase is compressed.",
    "G7 15 Day: FDA cleared 4/10/2025 (US); Health Canada authorized 7/13/2026 — 15.5-day wear, 8.0% MARD, fewer sensor changes."
  ],
  "body_markdown": "## Current Thesis\nDexCom is the CGM leader working a recovery that has shifted from event-driven pops to an analyst-revision grind, and mid-July added fresh fuel: Mizuho reiterated Outperform and lifted its target to $90 (7/15), Truist maintained Buy and raised to $87 (7/16), and the stock jumped ~7.2% on 7/16 to close $77.98 before easing to $76.65 on 7/17. Underneath, the June catalyst leg — ADA (6/5–8), CONNECT Type 2 non-insulin data (6/8), OTC pediatric / Stelo expansion (6/15) — has already printed, so the tape now rides sell-side revisions and rollout execution rather than fresh acceleration. The confirmed binary is the Q2 report after the close on July 30. Price sits in the high-the published invalidation levels, still contending with the 200-EMA, inside a 52-week range of $54.11–$89.98, with consensus PT ~$85 across 27 analysts (Strong Buy) sitting only modestly above spot. Buying at current levels pays up for a two-day pop into an earnings print nine trading days out. The medtech-diagnostics theme reads MATURING — sponsorship is broadening on revisions, but the catalyst leg has aged.\n\n## Bull Case\n- **Analyst revisions still climbing.** Mizuho Outperform PT $90 (7/15) and Truist Buy PT $87 (7/16) extend the late-June cluster (Deutsche Bank Buy $86 initiation 6/23, Piper $88 on 6/15, TD Cowen $95 on 6/10, Stifel $90 on 6/5). Consensus PT ~$85 across 27 analysts, rated Strong Buy.\n- **Product cycle widening geographically.** Health Canada authorized the G7 15 Day CGM (7/13) — 15.5-day wear, 8.0% MARD — extending to Canada the longest-wear, most-accurate system the FDA cleared in the US on 4/10/2025. Fewer sensor changes feed the gross-margin and adherence narratives.\n- **Type 2 non-insulin TAM is data-backed.** CONNECT (reported 6/8) showed G7 cut A1C 1.6% over 26 weeks in Type 2 patients not on insulin — the largest unpenetrated CGM cohort, tens of millions of US adults beyond the insulin-using base already served.\n- **OTC / cash-pay channel expanding.** The OTC pediatric CGM clearance plus the Stelo pediatric expansion (6/15) open a retail demographic outside the prescription funnel.\n- **Sector bid confirmed by the tape.** The ~7.2% single-session advance on 7/16 shows the CGM complex still pulls in capital on the analyst wave rather than fading post-catalyst.\n\n## Bear Case\n- **Chasing a two-day pop into a binary.** The 7/16 +7.2% spike lands nine trading days before the 7/30 Q2 print, and consensus PT ~$85 sits only modestly over the high-the published invalidation levels tape — reward/risk is compressed into an earnings event.\n- **Bounce, not breakout.** Price is still working the 200-EMA from below after a beaten-down base (52-week low $54.11), and the June advance ran on subdued volume (~0.74x average). A confirmed trend needs a 200-EMA reclaim on expanding volume, which has not printed.\n- **A1C data is not reimbursement.** The Type 2 non-insulin TAM only monetizes once payers cover it, and coverage typically lags clinical wins by several quarters; no broad coverage decision has landed.\n- **Competitive overhang.** An Abbott Libre price/share headline, or a lost pump-integration slot at Insulet or Tandem, can snap an unconfirmed advance quickly. The GLP-1 displacement worry (Lilly/Novo) remains the structural question under the whole CGM complex.\n- **Guidance risk on 7/30.** DexCom carries a history of violent post-print reactions; a Q2 revenue or full-year guide miss would unwind the revision-grind narrative fast given how far targets already sit above the tape.\n\n## Setup & Price Structure\n- Spot $76.65 (7/17 close) after a +7.2% session to $77.98 on 7/16; 7/17 day range $75.95–$78.01; 52-week range $54.11–$89.98.\n- The move reclaimed the high-the published invalidation levels, the upper end of the multi-month ~the published invalidation level–80 recovery range. A close over $80 on volume would signal the range is resolving up ahead of the print.\n- Support: the the published invalidation level–71 shelf (round number plus recovery base) defines the bounce; losing it ends the recovery structure.\n- Resistance: overhead supply from the prior breakdown zone and the $85–95 analyst-target band; the 52-week high $89.98 caps the current visible range.\n- Volume is the swing factor. The June leg ran ~0.74x average; a 200-EMA reclaim on >1.3x volume converts the bounce to a trend, while a fade back under $72 keeps price rangebound into earnings.\n\n## Catalyst Calendar (next 30 days)\n- **2026-07-30 (confirmed):** Q2 2026 earnings release after the close, 4:30 p.m. ET conference call — the dominant binary. Revenue, US organic growth, and full-year guidance are the swing variables.\n- **Ongoing analyst-revision flow:** most recent Mizuho $90 (7/15) and Truist $87 (7/16); further pre-print target moves are likely to cluster into late July.\n- **Rollout watch (no fixed date):** G7 15 Day commercial ramp following the Health Canada authorization (7/13) and US availability; a payer coverage decision for Type 2 non-insulin is the awaited monetization signal.\n\n## What Would Change Our Mind\n- a daily close that breaches the risk threshold loses the recovery-base shelf and round number; a weekly close that loses the 20-EMA confirms the break on the higher timeframe.\n- A Q2 miss or a full-year guide-down on 7/30 invalidates the revision-grind thesis regardless of the chart.\n- On the constructive side, a 200-EMA reclaim on >1.3x volume, or a decisive close over $80 before the print, flips the read from paying up for extension to a confirmed breakout worth pressing.\n- An Abbott Libre price/share headline, a lost Insulet/Tandem integration slot, or the medtech-diagnostics theme flipping to SATURATED would break the bull case on the fundamental side.\n\n## Correlation Notes\n- Tightest read is the CGM / insulin-delivery cluster: Abbott (Libre, the direct CGM competitor), Insulet (PODD) and Tandem (TNDM) pump integrations, and Medtronic diabetes. A Libre share or pricing move is the most direct threat to the tape.\n- Structural overhang from the GLP-1 leaders Lilly (LLY) and Novo Nordisk (NVO): the bear framing is that weight-loss drugs shrink the diabetic CGM funnel; the counter is CONNECT's Type 2 non-insulin data widening the base.\n- Group beta to medtech-devices-diagnostics, plus long-duration growth-multiple sensitivity to rate moves. For the next two weeks, idiosyncratic earnings risk on 7/30 dominates any sector correlation.",
  "first_seen": "2026-06-09",
  "last_analyzed": "2026-07-18T08:44:49+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}